Skip to main content
. 2022 Feb 21;12(2):340. doi: 10.3390/biom12020340

Figure 4.

Figure 4

Efficacy. (A) Clinical response in MS patients: Proportion of patients with improved EDSS status: 0.30 (95% CI: 0.17–0.46). (B) Comparison in clinical response by administration route in MS patients: the proportion of patients who improved their EDSS status in the IT group was 0.34 (95% CI: 0.17–0.57), in the IV group 0.16 (95% CI: 0.10–0.26). The subgroup differences were not significant, χ2 = 3.11 and p = 0.078.